Treatment outcomes of patients with spinal metastases derived from hepatocellular carcinoma
- 114 Downloads
The prognosis of hepatocellular carcinoma (HCC) used to be poor, but it has recently improved, which has meant that clinicians have greater opportunity to treat spinal metastases and the associated epidural spinal cord compression. However, there have been few systematic functional studies about HCC-derived spinal metastases. The treatment outcomes of surgical treatment for HCC-derived metastatic spinal tumors were investigated.
The post-treatment survival period and pain, paralysis, and disturbance of activities of daily living (ADL) were investigated in 60 patients (surgery 25, conservative treatment 35).
The mean post-treatment survival period was 7.4 ± 8.2 months (range 0.3–36 months). Univariate analysis indicated that the following factors influenced survival: the patient’s general condition, presence/absence of major internal organ metastasis, serum albumin level, Child–Pugh classification, surgical treatment for spinal metastasis, and bone-modifying agent treatment. In the multivariate analysis of these 6 items, 3 significant factors were extracted: the patient’s general condition, the serum albumin level, and bone-modifying agent treatment. Pain significantly improved in both groups (p < 0.001). Paralysis did not change significantly in the surgical group (p = 0.575), but it was significantly aggravated in the conservative treatment group (p = 0.047). The ADL abilities of the surgical group improved significantly (p < 0.001).
Most patients exhibited poor survival. In the conservative treatment group, paralysis was significantly aggravated, and little improvement was seen in the patients’ ADL abilities. In the surgical group, the patients’ ADL abilities improved significantly, but their paralysis did not. Therefore, surgery should be actively performed for HCC-derived spinal metastasis whenever it is indicated.
KeywordsMetastatic spinal tumor Hepatocellular carcinoma Treatment outcome Barthel index Survival period Activities of daily living
We would like to thank all of the members of staff at Nihon University Itabashi Hospital.
Compliance with ethical standards
Conflict of interest
No author has any conflict of interest.
IRB approval from Nihon University Itabashi Hospital: RK-11209-8.
- 2.Tralhao JG, Dagher I, Lino T et al (2007) Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 33:746–751Google Scholar
- 6.Rades D, Dahlke M, Janssen S et al (2015) Radiation therapy for metastatic spinal cord compression in patients with hepatocellular carcinoma. In vivo (Athens Greece) 29:749–752Google Scholar
- 11.Prodinger B, O’Connor RJ, Stucki G et al (2017) Establishing score equivalence of the Functional Independence Measure motor scale and the Barthel index, utilising the international classification of functioning, disability and health and Rasch measurement theory. J Rehabil Med 49: 416–422CrossRefGoogle Scholar
- 14.Hsiao SY, Chen SF, Chang CC et al (2011) Central nervous system involvement in hepatocellular carcinoma: clinical characteristics and comparison of intracranial and spinal metastatic groups. J Clin Neurosci Off J Neurosurg Soc Australas 18:364–368Google Scholar
- 16.Goodwin CR, Yanamadala V, Ruiz-Valls A et al (2016) A systematic review of metastatic hepatocellular carcinoma to the spine. World Neurosurg 91(510–517):e514Google Scholar
- 17.Ryo H, Sakai H, Yoneda S et al (1998) Bone metastasis of primary lung cancer. Nihon Kokyuki Gakkai zasshi J Jpn Respiratory Soc 36:317–322Google Scholar